Results 131 to 140 of about 19,645 (254)
Vesicular Ganglioside GM1 From Breast Tumor Cells Stimulated Epithelial-to-Mesenchymal Transition of Recipient MCF-10A Cells. [PDF]
Ma Q +5 more
europepmc +1 more source
GM1 ganglioside prevents axonal regeneration inhibition and cognitive deficits in a mouse model of traumatic brain injury [PDF]
Amit Benady +3 more
openalex +1 more source
Alzheimer's disease (AD) is a progressive neurodegenerative disease that accounts for two-thirds of all dementia cases, and age is the strongest risk factor. In addition to the amyloid hypothesis, lipid dysregulation is now recognized as a core component
Wenxuan Wang +3 more
doaj +1 more source
GM1 ganglioside improves dopaminergic markers of rat mesencephalic cultures treated with MPP+ [PDF]
A Dalia +2 more
openalex +1 more source
Ganglioside-magnetosome complex formation enhances uptake of gangliosides by cells
Feng Guan,1 Xiang Li,1 Jia Guo,1 Ganglong Yang,1 Xiang Li2 1The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, 2Wuxi Medical School, Jiangnan University, Wuxi, People’s Republic of China ...
Guan F, Li X, Guo J, Yang G, Li X
doaj
Distribution of Gangliosides, GM1 and GM3, in the Rat Oviduct
It is known that gangliosides, being ubiquitous membrane components, play important roles in cell-cell recognition, differentiation and transmembrane signalling. GM3, GM1 and GD1a were detected in the rat oviduct as major gangliosides by thin-layer chromatography (TLC) analysis. The total amounts of gangliosides from the oviducts at various times after
openaire +2 more sources
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease [PDF]
Jay S. Schneider +5 more
openalex +1 more source
Marked efficacy of Rituximab in multifocal motor neuropathy associated with chronic lymphocytic leukemia [PDF]
The authors describe a patient who presented a multifocal motor neuropathy (MMN) associated with a high anti-ganglioside antibody (anti-GM1 and anti-GD1) titer at the clinical onset of a B-cell chronic lymphocytic leukemia (B-CLL). Immunomodulation (IVIg
Antonella Di, Pasquale +6 more
core

